Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
NGM Biopharmaceuticals appoints Siobhan Nolan Mangini CFO » 16:16
05/27/20
05/27
16:16
05/27/20
16:16
NGM

NGM Biopharmaceuticals

$20.24 /

-0.44 (-2.13%)

NGM Biopharmaceuticals…

NGM Biopharmaceuticals announced the appointment of Siobhan Nolan Mangini as CFO. In her role as CFO, which will take effect on July 13, Nolan Mangini will oversee finance, business development and investor relations at NGM. Nolan Mangini most recently served as President and CFO of Castlight Health.

ShowHide Related Items >><<
NGM NGM Biopharmaceuticals
$20.24 /

-0.44 (-2.13%)

NGM NGM Biopharmaceuticals
$20.24 /

-0.44 (-2.13%)

05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/27/20 Citi
NGM Biopharmaceuticals price target lowered to $28 from $34 at Citi
NGM NGM Biopharmaceuticals
$20.24 /

-0.44 (-2.13%)

NGM NGM Biopharmaceuticals
$20.24 /

-0.44 (-2.13%)

NGM NGM Biopharmaceuticals
$20.24 /

-0.44 (-2.13%)

Conference/Events
Roth Capital biotech analysts to hold an analyst/industry conference call » 14:25
05/26/20
05/26
14:25
05/26/20
14:25
AKRO

Akero Therapeutics

$24.92 /

+0.71 (+2.93%)

, ALT

Altimmune

$8.45 /

+1.51 (+21.76%)

, ENTA

Enanta

$55.90 /

+0.78 (+1.42%)

, GLMD

Galmed

$5.51 /

-0.29 (-5.00%)

, GNFT

Genfit

$5.26 /

+0.02 (+0.38%)

, HEPA

Hepion Pharmaceuticals

$1.94 /

-0.05 (-2.51%)

, ICPT

Intercept

$77.59 /

-2.95 (-3.66%)

, MDGL

Madrigal Pharmaceuticals

$123.16 /

-2.67 (-2.12%)

, NGM

NGM Biopharmaceuticals

$21.22 /

+1.04 (+5.15%)

Biotech Analysts, along…

Biotech Analysts, along with Dr. Eric Lawitz, discuss Non-Alcoholic SteatoHepatitis (NASH) on an Analyst/Industry conference call to be held on May 26 at 3 pm.

ShowHide Related Items >><<
NGM NGM Biopharmaceuticals
$21.22 /

+1.04 (+5.15%)

MDGL Madrigal Pharmaceuticals
$123.16 /

-2.67 (-2.12%)

ICPT Intercept
$77.59 /

-2.95 (-3.66%)

HEPA Hepion Pharmaceuticals
$1.94 /

-0.05 (-2.51%)

GNFT Genfit
$5.26 /

+0.02 (+0.38%)

ENTA Enanta
$55.90 /

+0.78 (+1.42%)

ALT Altimmune
$8.45 /

+1.51 (+21.76%)

AKRO Akero Therapeutics
$24.92 /

+0.71 (+2.93%)

AKRO Akero Therapeutics
$24.92 /

+0.71 (+2.93%)

03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/02/20 H.C. Wainwright
Akero Therapeutics initiated with a Buy at H.C. Wainwright
02/13/20 Roth Capital
Akero Therapeutics price target raised to $43 from $34 at Roth Capital
02/10/20 Canaccord
Akero Therapeutics initiated with a Buy at Canaccord
ALT Altimmune
$8.45 /

+1.51 (+21.76%)

05/06/20 Roth Capital
Novo data 'sets up the runway' for Altimmune, says Roth Capital
04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
02/24/20
Fly Intel: Top five analyst initiations
ENTA Enanta
$55.90 /

+0.78 (+1.42%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
GLMD Galmed
$5.51 /

-0.29 (-5.00%)

05/22/20
Fly Intel: Top five analyst downgrades
05/22/20 B. Riley FBR
B. Riley FBR downgrades Galmed, cuts target to $8 from $11
05/22/20 B. Riley FBR
Galmed downgraded to Neutral from Buy at B. Riley FBR
05/15/20 H.C. Wainwright
Galmed price target lowered to $29 from $34 at H.C. Wainwright
GNFT Genfit
$5.26 /

+0.02 (+0.38%)

05/22/20 B. Riley FBR
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR
05/13/20 Bryan Garnier
Genfit downgraded to Neutral from Buy at Bryan Garnier
05/13/20 Kepler Cheuvreux
Genfit downgraded to Reduce from Buy at Kepler Cheuvreux
05/12/20 B. Riley FBR
Genfit downgraded to Neutral from Buy at B. Riley FBR
HEPA Hepion Pharmaceuticals
$1.94 /

-0.05 (-2.51%)

03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
11/22/19 Brookline
Hepion Pharmaceuticals initiated with a Buy at Brookline
11/07/19
Fly Intel: Top analyst initiations
11/07/19 Roth Capital
Hepion Pharmaceuticals initiated with a Buy at Roth Capital
ICPT Intercept
$77.59 /

-2.95 (-3.66%)

05/22/20 B. Riley FBR
Intercept weakness on 'slight' delay should be bought, says B. Riley FBR
05/22/20 Raymond James
Intercept downgraded at Raymond James after OCA NDA is postponed
05/22/20 Raymond James
Intercept downgraded to Outperform from Strong Buy at Raymond James
05/22/20 Stifel
Intercept uncertainty, lack of clarity in NASH to hurt sentiment, says Stifel
MDGL Madrigal Pharmaceuticals
$123.16 /

-2.67 (-2.12%)

05/08/20 H.C. Wainwright
Madrigal Pharmaceuticals price target lowered to $168 from $215 at H.C. Wainwright
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
05/05/20 Chardan
Madrigal Pharmaceuticals initiated with a Buy at Chardan
NGM NGM Biopharmaceuticals
$21.22 /

+1.04 (+5.15%)

05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/27/20 Citi
NGM Biopharmaceuticals price target lowered to $28 from $34 at Citi
NGM NGM Biopharmaceuticals
$21.22 /

+1.04 (+5.15%)

MDGL Madrigal Pharmaceuticals
$123.16 /

-2.67 (-2.12%)

ICPT Intercept
$77.59 /

-2.95 (-3.66%)

GLMD Galmed
$5.51 /

-0.29 (-5.00%)

ENTA Enanta
$55.90 /

+0.78 (+1.42%)

ALT Altimmune
$8.45 /

+1.51 (+21.76%)

AKRO Akero Therapeutics
$24.92 /

+0.71 (+2.93%)

ICPT Intercept
$77.59 /

-2.95 (-3.66%)

GNFT Genfit
$5.26 /

+0.02 (+0.38%)

NGM NGM Biopharmaceuticals
$21.22 /

+1.04 (+5.15%)

MDGL Madrigal Pharmaceuticals
$123.16 /

-2.67 (-2.12%)

ICPT Intercept
$77.59 /

-2.95 (-3.66%)

GNFT Genfit
$5.26 /

+0.02 (+0.38%)

ALT Altimmune
$8.45 /

+1.51 (+21.76%)

AKRO Akero Therapeutics
$24.92 /

+0.71 (+2.93%)

NGM NGM Biopharmaceuticals
$21.22 /

+1.04 (+5.15%)

ICPT Intercept
$77.59 /

-2.95 (-3.66%)

ALT Altimmune
$8.45 /

+1.51 (+21.76%)

AKRO Akero Therapeutics
$24.92 /

+0.71 (+2.93%)

Conference/Events
Roth Capital biotech analysts to hold an analyst/industry conference call » 09:42
05/26/20
05/26
09:42
05/26/20
09:42
AKRO

Akero Therapeutics

$24.21 /

+ (+0.00%)

, ALT

Altimmune

$6.94 /

+ (+0.00%)

, ENTA

Enanta

$55.12 /

+ (+0.00%)

, GLMD

Galmed

$5.80 /

+ (+0.00%)

, GNFT

Genfit

$5.24 /

+ (+0.00%)

, HEPA

Hepion Pharmaceuticals

$1.99 /

+ (+0.00%)

, ICPT

Intercept

$80.54 /

+ (+0.00%)

, MDGL

Madrigal Pharmaceuticals

$125.83 /

+ (+0.00%)

, NGM

NGM Biopharmaceuticals

$20.18 /

+ (+0.00%)

Biotech Analysts, along…

Biotech Analysts, along with Dr. Eric Lawitz, discuss Non-Alcoholic SteatoHepatitis (NASH) on an Analyst/Industry conference call to be held on May 26 at 3 pm.

ShowHide Related Items >><<
NGM NGM Biopharmaceuticals
$20.18 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$125.83 /

+ (+0.00%)

ICPT Intercept
$80.54 /

+ (+0.00%)

HEPA Hepion Pharmaceuticals
$1.99 /

+ (+0.00%)

GNFT Genfit
$5.24 /

+ (+0.00%)

ENTA Enanta
$55.12 /

+ (+0.00%)

ALT Altimmune
$6.94 /

+ (+0.00%)

AKRO Akero Therapeutics
$24.21 /

+ (+0.00%)

AKRO Akero Therapeutics
$24.21 /

+ (+0.00%)

03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/02/20 H.C. Wainwright
Akero Therapeutics initiated with a Buy at H.C. Wainwright
02/13/20 Roth Capital
Akero Therapeutics price target raised to $43 from $34 at Roth Capital
02/10/20 Canaccord
Akero Therapeutics initiated with a Buy at Canaccord
ALT Altimmune
$6.94 /

+ (+0.00%)

05/06/20 Roth Capital
Novo data 'sets up the runway' for Altimmune, says Roth Capital
04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
02/24/20
Fly Intel: Top five analyst initiations
ENTA Enanta
$55.12 /

+ (+0.00%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
GLMD Galmed
$5.80 /

+ (+0.00%)

05/22/20
Fly Intel: Top five analyst downgrades
05/22/20 B. Riley FBR
B. Riley FBR downgrades Galmed, cuts target to $8 from $11
05/22/20 B. Riley FBR
Galmed downgraded to Neutral from Buy at B. Riley FBR
05/15/20 H.C. Wainwright
Galmed price target lowered to $29 from $34 at H.C. Wainwright
GNFT Genfit
$5.24 /

+ (+0.00%)

05/22/20 B. Riley FBR
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR
05/13/20 Bryan Garnier
Genfit downgraded to Neutral from Buy at Bryan Garnier
05/13/20 Kepler Cheuvreux
Genfit downgraded to Reduce from Buy at Kepler Cheuvreux
05/12/20 B. Riley FBR
Genfit downgraded to Neutral from Buy at B. Riley FBR
HEPA Hepion Pharmaceuticals
$1.99 /

+ (+0.00%)

03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
11/22/19 Brookline
Hepion Pharmaceuticals initiated with a Buy at Brookline
11/07/19
Fly Intel: Top analyst initiations
11/07/19 Roth Capital
Hepion Pharmaceuticals initiated with a Buy at Roth Capital
ICPT Intercept
$80.54 /

+ (+0.00%)

05/22/20 B. Riley FBR
Intercept weakness on 'slight' delay should be bought, says B. Riley FBR
05/22/20 Raymond James
Intercept downgraded at Raymond James after OCA NDA is postponed
05/22/20 Raymond James
Intercept downgraded to Outperform from Strong Buy at Raymond James
05/22/20 Stifel
Intercept uncertainty, lack of clarity in NASH to hurt sentiment, says Stifel
MDGL Madrigal Pharmaceuticals
$125.83 /

+ (+0.00%)

05/08/20 H.C. Wainwright
Madrigal Pharmaceuticals price target lowered to $168 from $215 at H.C. Wainwright
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
05/05/20 Chardan
Madrigal Pharmaceuticals initiated with a Buy at Chardan
NGM NGM Biopharmaceuticals
$20.18 /

+ (+0.00%)

05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/27/20 Citi
NGM Biopharmaceuticals price target lowered to $28 from $34 at Citi
NGM NGM Biopharmaceuticals
$20.18 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$125.83 /

+ (+0.00%)

ICPT Intercept
$80.54 /

+ (+0.00%)

GLMD Galmed
$5.80 /

+ (+0.00%)

ENTA Enanta
$55.12 /

+ (+0.00%)

ALT Altimmune
$6.94 /

+ (+0.00%)

AKRO Akero Therapeutics
$24.21 /

+ (+0.00%)

ICPT Intercept
$80.54 /

+ (+0.00%)

GNFT Genfit
$5.24 /

+ (+0.00%)

NGM NGM Biopharmaceuticals
$20.18 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$125.83 /

+ (+0.00%)

ICPT Intercept
$80.54 /

+ (+0.00%)

GNFT Genfit
$5.24 /

+ (+0.00%)

ALT Altimmune
$6.94 /

+ (+0.00%)

AKRO Akero Therapeutics
$24.21 /

+ (+0.00%)

NGM NGM Biopharmaceuticals
$20.18 /

+ (+0.00%)

ICPT Intercept
$80.54 /

+ (+0.00%)

ALT Altimmune
$6.94 /

+ (+0.00%)

AKRO Akero Therapeutics
$24.21 /

+ (+0.00%)

Earnings
NGM Biopharmaceuticals reports Q1 EPS (28c), consensus (27c) » 16:15
05/13/20
05/13
16:15
05/13/20
16:15
NGM

NGM Biopharmaceuticals

$21.45 /

-0.45 (-2.05%)

Reports Q1 revenue…

Reports Q1 revenue $24.36M, consensus $22.95M. "In the first quarter of 2020, we demonstrated strong execution across our broad pipeline in multiple therapeutic areas. As we continue to navigate the ever-evolving COVID-19 situation, we have been fortunate to continue to move forward with our programs, most notably with the initiation of our Phase 2b ALPINE 4 study of aldafermin in patients with compensated cirrhosis due to NASH, a very sick patient population for which there is no currently available treatment other than liver transplant," said David Woodhouse, CEO at NGM. "As previously announced, in the first quarter of 2020, we also initiated a Phase 1a/1b clinical study for NGM120 as a potential treatment for cancer and cancer anorexia/cachexia syndrome, or CACS, and a Phase 1 clinical study for NGM395 as a potential treatment for metabolic disease, bringing us to a total of six product candidates now in clinical development. As we advance our clinical programs during these uncertain and unsettling times, the safety and well-being of patients, healthcare workers and our employees remain our top priority. We are closely monitoring the impact of COVID-19 on our organization and business operations and, like others in our industry, are managing multiple challenges to mitigate disruptions in our ongoing and planned trials in order to remain on track with our development timelines. The high unmet medical needs targeted by each of our development programs provide strong motivation for us to remain focused on execution across our pipeline."

ShowHide Related Items >><<
NGM NGM Biopharmaceuticals
$21.45 /

-0.45 (-2.05%)

NGM NGM Biopharmaceuticals
$21.45 /

-0.45 (-2.05%)

05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/27/20 Citi
NGM Biopharmaceuticals price target lowered to $28 from $34 at Citi
NGM NGM Biopharmaceuticals
$21.45 /

-0.45 (-2.05%)

NGM NGM Biopharmaceuticals
$21.45 /

-0.45 (-2.05%)

NGM NGM Biopharmaceuticals
$21.45 /

-0.45 (-2.05%)

On The Fly
Novo Nordisk slips as analysts discuss NASH data, read-through to peers » 14:46
05/06/20
05/06
14:46
05/06/20
14:46
NVO

Novo Nordisk

$62.47 /

-0.81 (-1.28%)

, ICPT

Intercept

$89.74 /

+9.16 (+11.37%)

, NGM

NGM Biopharmaceuticals

$19.99 /

+2.06 (+11.49%)

, GNFT

Genfit

$21.09 /

-0.85 (-3.87%)

, ALT

Altimmune

$3.02 /

-0.11 (-3.51%)

, AKRO

Akero Therapeutics

$20.95 /

+0.27 (+1.31%)

, BMY

Bristol-Myers

$61.48 /

+0.13 (+0.21%)

, MDGL

Madrigal Pharmaceuticals

$88.54 /

-0.01 (-0.01%)

, VKTX

Viking Therapeutics

$6.64 /

-0.05 (-0.75%)

In conjunction with the…

Open Full Text

ShowHide Related Items >><<
NVO Novo Nordisk
$62.47 /

-0.81 (-1.28%)

05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
05/06/20 Roth Capital
Novo data 'sets up the runway' for Altimmune, says Roth Capital
05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
05/04/20
Fly Intel: Top five analyst initiations
ICPT Intercept
$89.74 /

+9.16 (+11.37%)

04/02/20 Chardan
Intercept initiated with a Buy at Chardan
03/19/20 JMP Securities
JMP Securities says report on Intercept's OCA 'favorable'
NGM NGM Biopharmaceuticals
$19.99 /

+2.06 (+11.49%)

04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/27/20 Citi
NGM Biopharmaceuticals price target lowered to $28 from $34 at Citi
GNFT Genfit
$21.09 /

-0.85 (-3.87%)

04/09/20 H.C. Wainwright
Genfit price target lowered to $46 from $58 at H.C. Wainwright
01/23/20 B. Riley FBR
Genfit selloff on data speculation unwarranted, says B. Riley FBR
ALT Altimmune
$3.02 /

-0.11 (-3.51%)

04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
02/24/20
Fly Intel: Top five analyst initiations
AKRO Akero Therapeutics
$20.95 /

+0.27 (+1.31%)

03/02/20 H.C. Wainwright
Akero Therapeutics initiated with a Buy at H.C. Wainwright
02/13/20 Roth Capital
Akero Therapeutics price target raised to $43 from $34 at Roth Capital
02/10/20 Canaccord
Akero Therapeutics initiated with a Buy at Canaccord
BMY Bristol-Myers
$61.48 /

+0.13 (+0.21%)

04/20/20 Piper Sandler
Exelixis combo approval would increase kidney cancer use, says Piper Sandler
04/02/20
Fly Intel: Top five analyst upgrades
04/02/20 Morgan Stanley
Bristol-Myers upgraded to Overweight after pullback at Morgan Stanley
04/02/20 Morgan Stanley
Bristol-Myers upgraded to Overweight from Equal Weight at Morgan Stanley
MDGL Madrigal Pharmaceuticals
$88.54 /

-0.01 (-0.01%)

05/05/20 Chardan
Madrigal Pharmaceuticals initiated with a Buy at Chardan
03/05/20 Citi
Madrigal Pharmaceuticals price target lowered to $155 from $166 at Citi
VKTX Viking Therapeutics
$6.64 /

-0.05 (-0.75%)

05/05/20 Chardan
Viking Therapeutics initiated with a Buy at Chardan
05/04/20 B. Riley FBR
Viking Therapeutics price target lowered to $12 from $16 at B. Riley FBR
05/01/20 BTIG
Viking Therapeutics initiated with a Buy at BTIG
02/27/20 H.C. Wainwright
Viking Therapeutics price target lowered to $18 from $31 at H.C. Wainwright
Recommendations
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals » 13:22
05/06/20
05/06
13:22
05/06/20
13:22
NGM

NGM Biopharmaceuticals

$19.39 /

+1.46 (+8.14%)

, NVO

Novo Nordisk

$62.62 /

-0.66 (-1.04%)

, ICPT

Intercept

$90.00 /

+9.42 (+11.69%)

, GNFT

Genfit

$21.10 /

-0.84 (-3.83%)

Stifel analyst Derek…

Stifel analyst Derek Archila noted that Novo Nordisk (NVO) indicated in conjunction with its earnings report that semaglutide demonstrated statistically significant results at all doses on the primary endpoint of NASH resolution without worsening of fibrosis in a phase 2 study in biopsy confirmed non-alcoholic steatohepatitis, or NASH, patients. However, management noted that the study did not the "important" secondary endpoint of fibrosis improvement without worsening of NASH, said Archila. Overall, he said Novo's study results "have little impact or are a slight positive" for NGM Biopharmaceuticals (NGM), whose aldafermin has demonstrated a fibrosis improvement in only 24 weeks compared to Novo's study length of 72 weeks. For Genfit (GNFT), he believes the high response rate seen for semaglutide sets "a high bar" for elafibranor in Phase 3 and views the results as "an incremental negative." For Intercept (ICPT), Archila views the lack of fibrosis improvement for semaglutide as "an incremental positive," though he remains cautious on OCA's uptake given its modest efficacy on fibrosis and "less than ideal safety profile."

ShowHide Related Items >><<
NGM NGM Biopharmaceuticals
$19.39 /

+1.46 (+8.14%)

04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/27/20 Citi
NGM Biopharmaceuticals price target lowered to $28 from $34 at Citi
02/26/20 B. Riley FBR
NGM Biopharmaceuticals price target raised to $30 from $24 at B. Riley FBR
NVO Novo Nordisk
$62.62 /

-0.66 (-1.04%)

05/04/20
Fly Intel: Top five analyst initiations
05/04/20 Cowen
Novo Nordisk initiated with a Market Perform at Cowen
03/23/20 UBS
Novo Nordisk upgraded to Buy from Neutral at UBS
03/16/20 BofA
Novo Nordisk upgraded to Buy from Neutral at BofA
ICPT Intercept
$90.00 /

+9.42 (+11.69%)

04/02/20 Chardan
Intercept initiated with a Buy at Chardan
03/19/20 JMP Securities
JMP Securities says report on Intercept's OCA 'favorable'
03/05/20 BofA
Intercept reinstated with a Neutral at BofA
02/26/20 Cantor Fitzgerald
Intercept shares attractive after pullback, says Cantor Fitzgerald
GNFT Genfit
$21.10 /

-0.84 (-3.83%)

04/09/20 H.C. Wainwright
Genfit price target lowered to $46 from $58 at H.C. Wainwright
01/23/20 B. Riley FBR
Genfit selloff on data speculation unwarranted, says B. Riley FBR
12/19/19 Roth Capital
Roth says Genfit 'unlocking the power' of non-invasive diagnosis of NASH
11/26/19 H.C. Wainwright
Favorable safety a positive for Genfit's elafibranor, says H.C. Wainwright
Conference/Events
NGM Biopharmaceuticals management to meet virtually with B.Riley FBR » 04:55
05/04/20
05/04
04:55
05/04/20
04:55
NGM

NGM Biopharmaceuticals

$16.62 /

-1.62 (-8.88%)

Meetings to be held…

Meetings to be held virtually May 3-4 hosted by B. Riley FBR.

ShowHide Related Items >><<
NGM NGM Biopharmaceuticals
$16.62 /

-1.62 (-8.88%)

04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/27/20 Citi
NGM Biopharmaceuticals price target lowered to $28 from $34 at Citi
02/26/20 B. Riley FBR
NGM Biopharmaceuticals price target raised to $30 from $24 at B. Riley FBR
Over a month ago
Conference/Events
NGM Biopharmaceuticals management to meet virtually with B.Riley FBR » 04:55
05/03/20
05/03
04:55
05/03/20
04:55
NGM

NGM Biopharmaceuticals

$16.62 /

-1.62 (-8.88%)

Meetings to be held…

Meetings to be held virtually May 3-4 hosted by B. Riley FBR.

ShowHide Related Items >><<
NGM NGM Biopharmaceuticals
$16.62 /

-1.62 (-8.88%)

04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/27/20 Citi
NGM Biopharmaceuticals price target lowered to $28 from $34 at Citi
02/26/20 B. Riley FBR
NGM Biopharmaceuticals price target raised to $30 from $24 at B. Riley FBR
Conference/Events
Roth Capital biotech analyst to hold an analyst/industry conference call » 11:25
05/01/20
05/01
11:25
05/01/20
11:25
AKRO

Akero Therapeutics

$20.23 /

-0.26 (-1.27%)

, ALT

Altimmune

$2.92 /

-0.11 (-3.63%)

, ENTA

Enanta

$47.58 /

+1.2 (+2.59%)

, GLMD

Galmed

$4.25 /

-0.21 (-4.71%)

, GNFT

Genfit

$21.00 /

-0.6 (-2.78%)

, HEPA

Hepion Pharmaceuticals

$1.78 /

-0.1 (-5.32%)

, ICPT

Intercept

$77.05 /

-4.71 (-5.76%)

, MDGL

Madrigal Pharmaceuticals

$82.18 /

-1.5 (-1.79%)

, NGM

NGM Biopharmaceuticals

$16.50 /

-1.74 (-9.54%)

Biotechnology Analyst…

Biotechnology Analyst Rahimi, along with Dr. Juan Frias, discuss the effectiveness of GLP-1 agonists in improving liver histology in patients with NASH on an Analyst/Industry conference call to be held on May 1 at 12 pm.

ShowHide Related Items >><<
AKRO Akero Therapeutics
$20.23 /

-0.26 (-1.27%)

03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/02/20 H.C. Wainwright
Akero Therapeutics initiated with a Buy at H.C. Wainwright
02/13/20 Roth Capital
Akero Therapeutics price target raised to $43 from $34 at Roth Capital
02/10/20 Canaccord
Akero Therapeutics initiated with a Buy at Canaccord
ALT Altimmune
$2.92 /

-0.11 (-3.63%)

04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
02/24/20
Fly Intel: Top five analyst initiations
02/24/20 Roth Capital
Altimmune resumed with a Buy at Roth Capital
ENTA Enanta
$47.58 /

+1.2 (+2.59%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
GLMD Galmed
$4.25 /

-0.21 (-4.71%)

02/04/20 Craig-Hallum
Galmed initiated with a Buy at Craig-Hallum
01/30/20 Cantor Fitzgerald
Cantor sees valuation disconnect for Galmed. assumes with Overweight
01/30/20 Cantor Fitzgerald
Galmed assumed with an Overweight at Cantor Fitzgerald
12/02/19 Canaccord
Galmed initiated with a Buy at Canaccord
GNFT Genfit
$21.00 /

-0.6 (-2.78%)

04/09/20 H.C. Wainwright
Genfit price target lowered to $46 from $58 at H.C. Wainwright
01/23/20 B. Riley FBR
Genfit selloff on data speculation unwarranted, says B. Riley FBR
12/19/19 Roth Capital
Roth says Genfit 'unlocking the power' of non-invasive diagnosis of NASH
11/26/19 H.C. Wainwright
Favorable safety a positive for Genfit's elafibranor, says H.C. Wainwright
HEPA Hepion Pharmaceuticals
$1.78 /

-0.1 (-5.32%)

03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
11/22/19 Brookline
Hepion Pharmaceuticals initiated with a Buy at Brookline
11/07/19
Fly Intel: Top analyst initiations
11/07/19 Roth Capital
Hepion Pharmaceuticals initiated with a Buy at Roth Capital
ICPT Intercept
$77.05 /

-4.71 (-5.76%)

04/02/20 Chardan
Intercept initiated with a Buy at Chardan
03/19/20 JMP Securities
JMP Securities says report on Intercept's OCA 'favorable'
03/05/20 BofA
Intercept reinstated with a Neutral at BofA
02/26/20 Cantor Fitzgerald
Intercept shares attractive after pullback, says Cantor Fitzgerald
MDGL Madrigal Pharmaceuticals
$82.18 /

-1.5 (-1.79%)

03/05/20 Citi
Madrigal Pharmaceuticals price target lowered to $155 from $166 at Citi
01/30/20
Fly Intel: Top five analyst initiations
01/30/20 Canaccord
Madrigal Pharmaceuticals initiated with a Buy at Canaccord
NGM NGM Biopharmaceuticals
$16.50 /

-1.74 (-9.54%)

04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/27/20 Citi
NGM Biopharmaceuticals price target lowered to $28 from $34 at Citi
02/26/20 B. Riley FBR
NGM Biopharmaceuticals price target raised to $30 from $24 at B. Riley FBR
Conference/Events
NGM Biopharmaceuticals management to meet virtually with B.Riley FBR » 11:14
05/01/20
05/01
11:14
05/01/20
11:14
NGM

NGM Biopharmaceuticals

$16.69 /

-1.55 (-8.50%)

Meetings to be held…

Meetings to be held virtually May 3-4 hosted by B. Riley FBR.

ShowHide Related Items >><<
NGM NGM Biopharmaceuticals
$16.69 /

-1.55 (-8.50%)

04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/27/20 Citi
NGM Biopharmaceuticals price target lowered to $28 from $34 at Citi
02/26/20 B. Riley FBR
NGM Biopharmaceuticals price target raised to $30 from $24 at B. Riley FBR

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.